SGHT — Sight Sciences, Inc.

Summary of Sight Sciences Q3 2025 Earnings Call

1. Key Financial Results and Metrics

• Total Revenue: $19.9 million, a 1% decrease year-over-year.
• Surgical Glaucoma Revenue: $19.7 million, a 6% increase year-over-year, driven by more ordering accounts and higher average selling prices.
• Dry Eye Revenue: $0.2 million, down from $1.5 million, reflecting a strategic shift towards gaining reimbursement for TearCare.
• Gross Margin: 86%, up from 84% in the prior year; Surgical Glaucoma gross margin stable at 87%.
• Operating Expenses: $25.1 million, an 11% decrease from $28.1 million, attributed to lower stock-based compensation and personnel-related expenses.
• Net Loss: $8.2 million ($0.16 per share), improved from a net loss of $11.1 million ($0.22 per share) in the prior year.
• Cash Position: Ended the quarter with $92.4 million in cash and cash equivalents, and $40 million in debt.

2. Strategic Updates and Business Highlights

• Surgical Glaucoma: The company reported a return to growth, with a record number of active accounts and strong utilization metrics.
• TearCare: Recent establishment of reimbursement rates by two Medicare Administrative Contractors (MACs) is expected to enhance market access and drive growth in the Dry Eye segment.
• Management Changes: Ali Bauerlein was promoted to COO, and Jim Rodberg to CFO, both expected to drive operational excellence and strategic initiatives.
• Market Strategy: Focus on leveraging synergies between Surgical Glaucoma and Dry Eye segments, targeting eye care providers for increased adoption of TearCare.

3. Forward Guidance and Outlook

• 2025 Revenue Guidance: Raised to $76 million to $78 million, up from previous guidance of $72 million to $76 million.
• Fourth Quarter Expectations: Anticipated low single-digit growth in Surgical Glaucoma revenue compared to Q4 2024.
• Adjusted Operating Expense Guidance: Reduced to $90 million to $92 million for 2025, reflecting ongoing cost management efforts.
• TearCare Growth Potential: Expected to ramp significantly in 2026 as reimbursement coverage expands.

4. Challenges and Points of Concern

• Dry Eye Revenue Decline: The decrease in Dry Eye revenue is a concern, as the company shifts focus towards establishing reimbursement for TearCare.
• Tariff Costs: Continued exposure to tariffs impacting cost of goods sold, with expectations of $1 million to $1.5 million for the full year.
• Market Dynamics: The company faces competitive pressures in the Surgical Glaucoma market, particularly as competitors reposition their products and sales strategies.

5. Notable Q&A Insights

• Management Focus: COO Ali Bauerlein emphasized her commitment to scaling the TearCare franchise and increasing operational oversight.
• Reengagement of Dormant Accounts: Management noted that reengagement efforts with previously dormant accounts have been successful, contributing to growth.
• Future Payer Engagement: There is optimism regarding ongoing discussions with other payers following the establishment of fee schedules by Novitas and First Coast, with expectations for more coverage decisions in the near future.
• Competitive Landscape: CEO Paul Badawi highlighted the company's strong position in the MIGS market, emphasizing the importance of their established relationships with surgeons amidst competitive shifts.

This summary encapsulates the key financial results, strategic initiatives, forward guidance, challenges, and insights from the Q&A session, providing a comprehensive overview of Sight Sciences' performance and outlook.